Acetyl-CoA carboxylase

亜型選択性的な製品

ACC ACC1 ACC2

Acetyl-CoA carboxylase製品

All (8)
Acetyl-CoA carboxylase阻害剤 (7)
新製品

製品コード	製品名称	製品説明	文献中Selleckの製品使用例	お客様のフィードバック
S8893	Firsocostat (GS-0976, ND-630)	Firsocostat (GS-0976, ND-630) is a reversible inhibitor of acetyl CoA carboxylase (ACC) with IC50s of 2.1 nM,6.1 nM for hACC1 and hACC2,respectively.	Nat Commun, 2023, 14(1):1362 Genome Med, 2022, 14(1):67 Sci Adv, 2022, 8(47):eabq1984
S6753	CP 640186	CP 640186 is an isozyme-nonselective ACC (Acetyl-CoA carboxylase) inhibitor with IC50 values of 53 and 61 nM for rat liver ACC1 and rat skeletal muscle ACC2, respectively.	Exp Ther Med, 2020, 20(1):521-529 Molecules, 2015, 20(9):16221-34 Molecules, 2015, 20(9):16221-34
S8377	ND646	ND-646 is an allosteric inhibitor of the ACC (Acetyl-coA carboxylase) enzymes that prevents ACC subunit dimerization to suppress fatty acid synthesis with IC50 of 3.5 nM and 4.1 nM for hACC1 and hACC2, respectively.	Cancer Discov, 2023, 13(2):496-515 Cancer Sci, 2023, 114(4):1651-1662 Cancer Sci, 2023, 114(4):1651-1662
S6690	TOFA	TOFA is an allosteric inhibitor of acetyl-CoA carboxylase-α (ACCA). Inside the cell, TOFA is converted to TOFyl-CoA (5-tetradecyloxy-2-furoyl-CoA), exerting an allosteric inhibition on ACCA. TOFA blocks fatty acid synthesis and induces cell death in a dose-dependent manner.	bioRxiv, 2024, 2024.02.22.581432 Cancer Commun (Lond), 2022, 10.1002/cac2.12380 Sci Adv, 2021, 7(35)eabj0364
S6672	PF-05175157	PF-05175157 is a broad-spectrum effective ACC inhibitor with IC50 of 27.0 nM, 33.0 nM, 23.5 nM and 50.4 nM for human ACC1, human ACC2, rat ACC1, and rat ACC2, respectively.	Cancer Cell Int, 2023, 23(1):83
S5519	4-Methylsalicylic acid	4-Methylsalicylic acid (m-Cresotic acid, 2-Hydroxy-4-methylbenzoic acid, m-Cresotinic acid, 2-Hydroxy-p-toluic acid) is used to inhibit the medium chain acyl-CoA synthetase.
S6145	PF-05221304	PF-05221304 is an orally bioavailable, liver-targeted inhibitor of acetyl-CoA carboxylase (ACC), an enzyme that catalyzes the first committed step in de novo lipogenesis (DNL).
S6112	Oxalacetic acid	Oxalacetic acid (Oxaloacetic acid, 2-Oxosuccinic acid, Ketosuccinic acid) is an intermediate of the citric acid cycle, where it reacts with acetyl-CoA to form citrate, catalysed by citrate synthase. It is also involved in gluconeogenesis, urea cycle, glyoxylate cycle, amino acid synthesis, and fatty acid synthesis. Oxaloacetate is also a potent inhibitor of Complex II.
S8893	Firsocostat (GS-0976, ND-630)	Firsocostat (GS-0976, ND-630) is a reversible inhibitor of acetyl CoA carboxylase (ACC) with IC50s of 2.1 nM,6.1 nM for hACC1 and hACC2,respectively.	Nat Commun, 2023, 14(1):1362 Genome Med, 2022, 14(1):67 Sci Adv, 2022, 8(47):eabq1984
S6753	CP 640186	CP 640186 is an isozyme-nonselective ACC (Acetyl-CoA carboxylase) inhibitor with IC50 values of 53 and 61 nM for rat liver ACC1 and rat skeletal muscle ACC2, respectively.	Exp Ther Med, 2020, 20(1):521-529 Molecules, 2015, 20(9):16221-34 Molecules, 2015, 20(9):16221-34
S8377	ND646	ND-646 is an allosteric inhibitor of the ACC (Acetyl-coA carboxylase) enzymes that prevents ACC subunit dimerization to suppress fatty acid synthesis with IC50 of 3.5 nM and 4.1 nM for hACC1 and hACC2, respectively.	Cancer Discov, 2023, 13(2):496-515 Cancer Sci, 2023, 114(4):1651-1662 Cancer Sci, 2023, 114(4):1651-1662
S6690	TOFA	TOFA is an allosteric inhibitor of acetyl-CoA carboxylase-α (ACCA). Inside the cell, TOFA is converted to TOFyl-CoA (5-tetradecyloxy-2-furoyl-CoA), exerting an allosteric inhibition on ACCA. TOFA blocks fatty acid synthesis and induces cell death in a dose-dependent manner.	bioRxiv, 2024, 2024.02.22.581432 Cancer Commun (Lond), 2022, 10.1002/cac2.12380 Sci Adv, 2021, 7(35)eabj0364
S6672	PF-05175157	PF-05175157 is a broad-spectrum effective ACC inhibitor with IC50 of 27.0 nM, 33.0 nM, 23.5 nM and 50.4 nM for human ACC1, human ACC2, rat ACC1, and rat ACC2, respectively.	Cancer Cell Int, 2023, 23(1):83
S5519	4-Methylsalicylic acid	4-Methylsalicylic acid (m-Cresotic acid, 2-Hydroxy-4-methylbenzoic acid, m-Cresotinic acid, 2-Hydroxy-p-toluic acid) is used to inhibit the medium chain acyl-CoA synthetase.
S6145	PF-05221304	PF-05221304 is an orally bioavailable, liver-targeted inhibitor of acetyl-CoA carboxylase (ACC), an enzyme that catalyzes the first committed step in de novo lipogenesis (DNL).

Acetyl-CoA carboxylase阻害剤の選択性比較

Tags: Acetyl-CoA carboxylase inhibitor|Acetyl-CoA carboxylase agonist|Acetyl-CoA carboxylase activator|Acetyl-CoA carboxylase inducer|Acetyl-CoA carboxylase antagonist|Acetyl-CoA carboxylase signaling pathway|Acetyl-CoA carboxylase assay kit